Risks factors for graft failure, grade II-IV acute and chronic GVHD
| Outcomes . | Events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Graft failure | |||
| Age at transplantation, y | |||
| ≤6 | 49/638 | 1.00 | .02 |
| 7-15 | 43/439 | 1.30 (0.86-1.96) | .21 |
| 16-25 | 7/33 | 3.03 (1.36-6.73) | .006 |
| Donor type | |||
| HLA-matched relative | 58/677 | 1.00 | <.001 |
| HLA-mismatched relative | 17/78 | 2.84 (1.65-4.88) | <.001 |
| HLA-matched unrelated | 13/252 | 0.61 (0.33-1.11) | .10 |
| HLA-mismatched unrelated | 11/103 | 1.31 (0.68-2.50) | .42 |
| Acute GVHD | |||
| Age at transplantation, y | |||
| ≤6 | 93/634 | 1.00 | .002 |
| 7-15 | 78/436 | 1.10 (0.71-1.70) | .66 |
| 16-25 | 10/33 | 2.23 (1.30-3.84) | .003 |
| Donor type | |||
| HLA-matched relative | 80/674 | 1.00 | <.001 |
| HLA-mismatched relative | 27/77 | 3.33 (2.15-5.17) | <.001 |
| HLA-matched unrelated | 54/251 | 2.44 (1.72-3.46) | <.001 |
| HLA-mismatched unrelated | 20/101 | 1.94 (1.19-3.16) | .008 |
| Transplant period | |||
| 2012-2016 | 85/653 | 1.00 | <.001 |
| 2006-2011 | 68/338 | 1.70 (1.23-2.35) | .001 |
| 2000-2005 | 28/112 | 2.50 (1.61-4.00) | <.001 |
| Chronic GVHD | |||
| Donor type | |||
| HLA-matched relative | 52/627 | 1.00 | <.001 |
| HLA-mismatched relative | 14/70 | 2.64 (1.42-4.89) | .002 |
| HLA-matched unrelated | 21/249 | 2.13 (1.13-4.00) | .02 |
| HLA-mismatched unrelated | 24/101 | 4.25 (2.43-7.44) | <.001 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 17/372 | 1.00 | <.001 |
| Bu/Cy/FLU | 24/255 | 2.03 (1.09-3.78) | .03 |
| Bu/Cy | 41/223 | 6.78 (3.59-12.81) | <.001 |
| Treosulfan/TT/FLU | 20/140 | 7.25 (3.41-15.41) | <.001 |
| Bu or melphalan ± TT ± FLU | 9/57 | 1.94 (0.82-4.60) | .13 |
| Recipient sex | |||
| Male | 82/659 | 1.00 | |
| Female | 29/388 | 0.59 (0.38-0.91) | .02 |
| Outcomes . | Events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Graft failure | |||
| Age at transplantation, y | |||
| ≤6 | 49/638 | 1.00 | .02 |
| 7-15 | 43/439 | 1.30 (0.86-1.96) | .21 |
| 16-25 | 7/33 | 3.03 (1.36-6.73) | .006 |
| Donor type | |||
| HLA-matched relative | 58/677 | 1.00 | <.001 |
| HLA-mismatched relative | 17/78 | 2.84 (1.65-4.88) | <.001 |
| HLA-matched unrelated | 13/252 | 0.61 (0.33-1.11) | .10 |
| HLA-mismatched unrelated | 11/103 | 1.31 (0.68-2.50) | .42 |
| Acute GVHD | |||
| Age at transplantation, y | |||
| ≤6 | 93/634 | 1.00 | .002 |
| 7-15 | 78/436 | 1.10 (0.71-1.70) | .66 |
| 16-25 | 10/33 | 2.23 (1.30-3.84) | .003 |
| Donor type | |||
| HLA-matched relative | 80/674 | 1.00 | <.001 |
| HLA-mismatched relative | 27/77 | 3.33 (2.15-5.17) | <.001 |
| HLA-matched unrelated | 54/251 | 2.44 (1.72-3.46) | <.001 |
| HLA-mismatched unrelated | 20/101 | 1.94 (1.19-3.16) | .008 |
| Transplant period | |||
| 2012-2016 | 85/653 | 1.00 | <.001 |
| 2006-2011 | 68/338 | 1.70 (1.23-2.35) | .001 |
| 2000-2005 | 28/112 | 2.50 (1.61-4.00) | <.001 |
| Chronic GVHD | |||
| Donor type | |||
| HLA-matched relative | 52/627 | 1.00 | <.001 |
| HLA-mismatched relative | 14/70 | 2.64 (1.42-4.89) | .002 |
| HLA-matched unrelated | 21/249 | 2.13 (1.13-4.00) | .02 |
| HLA-mismatched unrelated | 24/101 | 4.25 (2.43-7.44) | <.001 |
| Conditioning regimen | |||
| Bu/Cy/TT/FLU | 17/372 | 1.00 | <.001 |
| Bu/Cy/FLU | 24/255 | 2.03 (1.09-3.78) | .03 |
| Bu/Cy | 41/223 | 6.78 (3.59-12.81) | <.001 |
| Treosulfan/TT/FLU | 20/140 | 7.25 (3.41-15.41) | <.001 |
| Bu or melphalan ± TT ± FLU | 9/57 | 1.94 (0.82-4.60) | .13 |
| Recipient sex | |||
| Male | 82/659 | 1.00 | |
| Female | 29/388 | 0.59 (0.38-0.91) | .02 |